Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s00280-017-3308-7
Published Online: 2017-04-19
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lau, Yvonne Y.
Gu, Wen
Lin, Tiffany
Viraswami-Appanna, Kalyanee
Cai, Can
Scott, Jeffrey W.
Shi, Michael
License valid from 2017-04-19